Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg

NCT01271998 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Bacterial Infection

Interventions

DRUG: TR-701 FA

Sponsor

Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)